title: Vasodilatory effects of adenosine A2 receptor agonists CGS 21680 and CGS 22492 in human vasculature.
abstract: The vasodilatory effects of the adenosine analogs, 5'-N-ethylcarboxamidoadenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl amino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) and 2-[(2-cyclohexylethyl)amino]adenosine (CGS 22492) in human coronary, internal mammary artery and saphenous vein were examined in vitro. All produced concentration-dependent relaxations in arterial as well as venous rings contracted with 35 mM KCl. The concentration-response curves for NECA and CGS 21680 were parallel in the coronary. The adenosine A2 receptor antagonist, 9-chloro-2-(2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS 15943A) significantly attenuated the relaxing response to the adenosine analogs in coronary artery. Although NECA and CGS 22492 were equally as effective at the highest concentration administered (both achieving approximately 70% relaxation at 10(-4) M) NECA (EC50 = 1.25 +/- 0.11 microM) induced greater vasodilation at lower concentrations than CGS 22492 (EC50 = 11.27 +/- 1.53 microM). CGS 21680 was the least potent of the agents tested achieving only 44% relaxation at 10(-4) M (EC50 = 4.71 +/- 0.46 microM). Coronary artery appeared to be more responsive than internal mammary artery or saphenous vein which displayed only marginal relaxation to these agents.
authors.affiliation: Department of Pharmacology, School of Medicine, East Carolina University, Greenville, NC 27858-4354.
authors.forename: S R
authors.initials: SR
authors.lastname: Makujina
authors.forename: M H
authors.initials: MH
authors.lastname: Sabouni
authors.forename: S
authors.initials: S
authors.lastname: Bhatia
authors.forename: F L
authors.initials: FL
authors.lastname: Douglas
authors.forename: S J
authors.initials: SJ
authors.lastname: Mustafa
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology; D003510:Cyclohexanes / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008323:Mammary Arteries / Q000187:drug effects / Q000502:physiology; D010627:Phenethylamines / Q000494:pharmacology*; D011983:Receptors, Purinergic / Q000187:drug effects*; D012501:Saphenous Vein / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D003510:Cyclohexanes; D010627:Phenethylamines; D011983:Receptors, Purinergic; D014665:Vasodilator Agents; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C070485:2-((2-cyclohexylethyl)amino)adenosine; D019830:Adenosine-5'-(N-ethylcarboxamide); D000241:Adenosine